Pregabalin Capsule
Product Images NDC 51407-579

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 51407-579). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-574-90.jpg (51407 574 90)

Label for Pregabalin 25 mg capsules by Golden State Medical Supply, Inc., containing 90 capsules. The label includes the NDC 51407-574-90 and states the product is for prescription use only. It mentions storage instructions and dispensing requirements, along with a pharmacist note to provide the medication guide to patients.*

FDA Label Image

51407-575-90.jpg (51407 575 90)

Pregabalin 50 mg capsules label showing product name, dosage strength, and form. The label indicates a 90-capsule count package with the Rx only designation. It includes dispensing instructions, storage conditions, and marketer information for GSMS Incorporated. A barcode and QR code are also visible.*

FDA Label Image

51407-576-90.jpg (51407 576 90)

Label for Pregabalin 75 mg capsules from Golden State Medical Supply, Inc., containing 90 capsules. The label includes dosage strength, instructions to dispense medication guide, storage conditions, and child-resistant container warning. Marketed by GSMS, Incorporated in Camarillo, CA.*

FDA Label Image

51407-577-90.jpg (51407 577 90)

Label for Pregabalin 100 mg capsules by Golden State Medical Supply Inc., NDC 51407-577-90. The label indicates 90 capsules per container, oral dosage form, and prescription only. Storage instructions, pharmacist guidance, and patient medication guide link are included, with a barcode and marketing info for GSMS Incorporated in Camarillo, CA.*

FDA Label Image

51407-578-90.jpg (51407 578 90)

Label for Pregabalin 150 mg capsules by Golden State Medical Supply, Inc. The label includes the NDC 51407-578-90, states 90 capsules per container, and marks the product as Rx only. It features usage instructions, storage conditions, a barcode, and a link to the medication guide.*

FDA Label Image

51407-579-90.jpg (51407 579 90)

Label for Pregabalin 200 mg capsules by Golden State Medical Supply, Inc. The label includes the NDC 51407-579-90 and states the package contains 90 capsules. It notes pharmacists should dispense the medication guide and provides storage instructions along with a barcode and marketing information from GSMS Incorporated, Camarillo, CA.*

FDA Label Image

51407-580-90.jpg (51407 580 90)

Pregabalin 225 mg capsules label from Golden State Medical Supply, Inc. The label displays the product name, dosage strength, and quantity of 90 capsules. It includes storage instructions, a barcode, NDC 51407-580-90, and directions to dispense with the medication guide. The label indicates prescription-only status.*

FDA Label Image

51407-581-90.jpg (51407 581 90)

Label for Pregabalin 300 mg capsules by Golden State Medical Supply, Inc., containing 90 capsules. The label includes NDC 51407-581-90, directions for pharmacists to dispense the Medication Guide, storage instructions at 25°C with permitted excursions, and the manufacturer address in Camarillo, CA. It states Rx only and child-resistant container requirements.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and Placebo, with varying improvement percentages across the pain improvement scale.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percent of patients improved against percent improvement in pain from baseline for Pregabalin 100 mg three times a day versus placebo. The graph shows two descending curves, with Pregabalin consistently above placebo, indicating a higher percentage of patient improvement across varying pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved based on percent improvement in pain from baseline for Pregabalin capsules at 75 mg, 150 mg, and 300 mg doses taken twice daily compared to placebo. The graph plots percent improvement in pain on the horizontal axis against the percent of patients improved on the vertical axis.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing percent improvement in pain from baseline with Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis shows the percent of patients improved, and the x-axis shows percent improvement in pain from 0 to 100 percent. Pregabalin 200 mg shows the highest percentage of patients improved across pain improvement levels, followed by Pregabalin 100 mg and placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The vertical axis is labeled percent of patients improved, and the horizontal axis represents percent improvement in pain.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

Bar chart comparing responder rates (%) in two clinical studies (E1 and E3) evaluating different doses of Pregabalin versus placebo. Study E1 shows increasing responder rates from placebo to 600 mg/day doses given BID. Study E3 compares placebo to 300 mg/day BID and 600 mg/day TID doses, with rates rising with dose. Statistically significant differences from placebo are indicated.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction (median percentage change from baseline) on the y-axis versus dose in mg/day on the x-axis. The graph compares four study groups (E1 BD, E2 TID, E3 BD, E3 TID) with plotted points and significant p-values noted. Dose ranges from 0 (placebo) to 600 mg/day are shown.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 800 mg, 450 mg, 300 mg daily doses, and placebo. The graph shows that higher daily doses of Pregabalin generally correspond to greater percentages of patient improvement in pain.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This is a line chart comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus Placebo. The y-axis represents the percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis shows the number of days from 0 to 180. The chart displays two lines: a solid line for Pregabalin and a dashed line for Placebo, illustrating different trends in subject outcomes over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12 BOCF. It includes two lines: a solid line representing Pregabalin and a dotted line representing Placebo, showing a higher percent of subjects improved with Pregabalin across the percent improvement range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved from baseline to week 16 according to the BOCF method for Pregabalin versus Placebo. The x-axis represents percent improvement, ranging from greater than 0% to 100%, and the y-axis shows the percent of subjects improved. Two curves are depicted: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin showing consistently higher improvement percentages.*

FDA Label Image

Figure 13 (Pregabalin Fig13)

A bar chart showing responder rates in percentage for three groups: Placebo (22.6%, N=93), 2.5 mg/kg/day Pregabalin dose (29.1%, N=103), and 10 mg/kg/day Pregabalin dose (40.6%, N=96). The vertical axis is labeled Responder Rate (%).*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula calculating creatinine clearance (CLcr) based on age in years, weight in kilograms, serum creatinine in mg/dL, with an adjustment factor of 0.85 for female patients. This formula is typically used for estimating renal function.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, the active ingredient in the product Pregabalin. The diagram shows the molecular arrangement including amino and carboxyl functional groups characteristic of this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.